Biotech Values

[north40000]

"If those pricing talks don't work--and Merck $MRK), at least, has said it's not interested in a price war--then insurers' only recourse will be to limit volume, Reimbursement Intelligence's John Whang told the news service. That presumably means strict prior authorization policies to direct expensive hep C drugs only to the sickest patients."

That also sounds like a lot of expensive law suits directed against insurance companies by patients who believe they are entitled to SOC drugs.